What are the NCCN guidelines for second-line chemotherapy regimens for osteosarcoma?

Updated: Dec 04, 2018
  • Author: Charles T Mehlman, DO, MPH; Chief Editor: Omohodion (Odion) Binitie, MD  more...
  • Print
Answer

For second-line therapy (relapsed/refractory or metastatic disease), NCCN recommendations are as follows [30] :

  • Docetaxel and gemcitabine
  • Cyclophosphamide and etoposide
  • Cyclophosphamide and topotecan
  • Gemcitabine
  • Ifosfamide (high dose) ± etoposide
  • Ifosfamide, carboplatin, and etoposide
  • High-dose methotrexate, etoposide, and ifosfamide
  • Samarium-153 ethylene diamine tetramethylene phosphonate (SM-EDTMP) for relapsed or refractory disease beyond second-line therapy
  • Radium-223
  • Sorafenib

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!